Explain this page
Arphra AIPlain-English read on Insulet Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.17% | +3.03% | -12.61% | -39.23% | -51.92% | -48.49% | -53.84% | -48.46% | -46.97% | +354.41% | +817.36% |
Aftermarket
LiveLast trade
$146.62
153 sh
Bid
$137.40
1 sh
Ask
$150.00
1 sh
Spread
$12.600
Sector & industry today
LiveSectors
- Technology+2.24%
- Utilities+1.75%
- Industrials+1.45%
- Healthcare+1.23%
- Real Estate+0.71%
- Energy+0.71%
- Basic Materials+0.12%
- Communication Services-0.51%
- Financial Services-0.55%
- Consumer Cyclical-0.63%
- Consumer Defensive-1.61%
Top industries (issuer's industry highlighted)
- Medical - Devices+0.76%
- Broadcasting+6.89%
- Oil & Gas Energy+4.23%
- Computer Hardware+4.09%
- Engineering & Construction+3.86%
- Software - Infrastructure+3.76%
- Financial - Capital Markets+3.44%
- Beverages - Non-Alcoholic-3.42%
- Semiconductors+3.32%
- Oil & Gas Drilling+3.28%
- Medical - Healthcare Information Services-3.05%
- Telecommunications Services-3.05%
Fair value
Football field →Weighted blend
$389.93
+166.33% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
4bull10bear
±5% threshold
Analyst PT consensus: $339.00 (+131.54%)
Total assets
$3.19B
Total debt
$1.05B
Cash & equiv
$716.1M
Operating CF
$569.3M
Free cash flow
$377.7M
Buybacks
-$59.6M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$339.00
+131.54% upside
Low
$220.00
Median
$330.00
High
$435.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessionsbusinesswire.com·Jun 04, 2026
- Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessionsbusinesswire.com·Jun 04, 2026
- Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcriptseekingalpha.com·Jun 03, 2026
- Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensorgurufocus.com·Jun 03, 2026
- Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensorbusinesswire.com·Jun 03, 2026
- Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- Here's Why Insulet (PODD) is a Strong Growth Stockzacks.com·May 12, 2026
- Insulet Reports First Quarter 2026 Resultsbusinesswire.com·May 06, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $783.8M | $101.6M | $1.44 |
| Q3 Sep 2025 | $706.3M | $87.6M | $1.24 |
| Q2 Jun 2025 | $649.1M | $22.5M | $0.32 |
| Q1 Mar 2025 | $569M | $35.4M | $0.50 |
| Q4 Dec 2024 | $597.5M | $100.7M | $1.39 |
| Q3 Sep 2024 | $543.9M | $77.5M | $1.08 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
MINOGUE MICHAEL R director | Buy | 2,030 | $499.85K | Feb 25, 2026 |
McEvoy Ashley director, officer: President and CEO | Buy | 4,300 | $1.03M | Feb 20, 2026 |
Frederick Wayne A.I. director | Sell | 1,851 | $542.51K | Dec 15, 2025 |
STONESIFER TIMOTHY C. director | Buy | 962 | $299.88K | Dec 05, 2025 |
Singh Prem officer: SVP, Global Operations | Sell | 687 | $238.73K | Sep 08, 2025 |
Cousin Laetitia officer: SVP, Reg, Quality & Compliance | Sell | 797 | $278K | Sep 08, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.71B | $473.8M | $247.1M | $3.48 | +9.12% |
| FY 2024 | $2.07B | $308.9M | $418.3M | $5.78 | +20.19% |
| FY 2023 | $1.7B | $220M | $206.3M | $2.94 | +12.16% |
| FY 2022 | $1.31B | $37.6M | $4.6M | $0.07 | +0.35% |
| FY 2021 | $1.1B | $126M | $16.8M | $0.25 | +1.53% |